28 January 2019 - Novartis has issued a statement expressing concern over the state of medicine supply to the UK, and noting that it is building increased inventories across its portfolio of medicines in the UK.

The move follows parliament's rejection of prime minister Theresa May's proposed Brexit deal.

The Switzerland-based pharmaceutical giant claimed that “the risk of UK exiting the EU without a deal is increased and this will be hugely impactful for patients, particularly around the supply and safety of medicine.”

Read Pharma Times article